Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs
https://www.zacks.com/stock/news/2266232/haemonetics-hae-banks-on-plasma-arm-growth-amid-rising-costs?cid=CS-ZC-FT-analyst_blog|zer_report_update-2266232
May 01, 2024 - Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
0
Here is Why Growth Investors Should Buy DexCom (DXCM) Now
https://www.zacks.com/stock/news/2265356/here-is-why-growth-investors-should-buy-dexcom-dxcm-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2265356
Apr 30, 2024 - DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
0
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
https://www.zacks.com/stock/news/2262800/dexcom-dxcm-q1-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2262800
Apr 25, 2024 - While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
https://www.zacks.com/commentary/2255364/3-medical-instruments-stocks-to-buy-amid-improving-industry-trends?cid=CS-ZC-FT-industry_outlook-2255364
Apr 15, 2024 - The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
0
Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree
https://www.zacks.com/stock/news/2249369/tenet-thc-divests-six-hospitals-sustains-divestiture-spree?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249369
Apr 02, 2024 - Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.
0
DexCom (DXCM) Upgraded to Buy: What Does It Mean for the Stock?
https://www.zacks.com/stock/news/2248016/dexcom-dxcm-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2248016
Mar 29, 2024 - DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
0
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2246003/has-dexcom-dxcm-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2246003
Mar 26, 2024 - Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
0
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
https://www.zacks.com/stock/news/2242241/reasons-to-retain-dexcom-dxcm-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242241
Mar 18, 2024 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
0
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
https://www.zacks.com/stock/news/2240686/buy-5-medical-devices-stocks-for-a-stable-portfolio-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240686
Mar 14, 2024 - We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
0
Community Health (CYH), Cost Plus Drugs Unite to Lower Drug Cost
https://www.zacks.com/stock/news/2237878/community-health-cyh-cost-plus-drugs-unite-to-lower-drug-cost?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237878
Mar 08, 2024 - Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.
0
Page 1>